WO1996030360A1 - Technique de production de derives de 1,4-benzodioxane - Google Patents
Technique de production de derives de 1,4-benzodioxane Download PDFInfo
- Publication number
- WO1996030360A1 WO1996030360A1 PCT/JP1996/000727 JP9600727W WO9630360A1 WO 1996030360 A1 WO1996030360 A1 WO 1996030360A1 JP 9600727 W JP9600727 W JP 9600727W WO 9630360 A1 WO9630360 A1 WO 9630360A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- carbon atoms
- producing
- benzodioxane
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
- C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D319/20—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring with substituents attached to the hetero ring
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Definitions
- the present invention relates to a method for producing a 1,4-benzodioxane derivative useful as a pharmaceutical intermediate such as a therapeutic agent for a cardiovascular disease and a therapeutic agent for a psychiatric nerve disease having ⁇ and / 5 adrenergic antagonistic activity.
- 1,4-Benzodioxane derivatives have been used as synthetic intermediates such as drugs for treating cardiovascular diseases and psychiatric drugs, which have antagonistic activity to na and S-adrenaline, and various methods are known for their production.
- a method of reacting a catechol derivative with glycidyl citrate in the presence of sodium hydride JP-A-6-9613
- a method of reacting a catechol derivative with epichlorohydrin in the presence of pyridine U. Org. Chem., 46, 38 46 (1981)).
- the method using glycidyl tosylate is expensive due to glycidyl tosylate and also requires hydrocracking.
- the epoxy group is reduced at the time of the deprotection, and the yield decreases.
- the method using epichlorohydrin removes the excess epichlorohydrin used by distilling off dichloropropanediol by-produced with xylene, and also removes the used hydrogen chloride and acetic acid by distilling with ethanol. Complicated operations are required.
- the reaction temperature is the reflux temperature of piperidine or hydrochloric acid, so that it cannot be used when the acid or base has an unstable substituent.
- the present inventors have conducted intensive studies to find an improved method of synthesizing a 1.4-benzodioxane derivative, and as a result, sulfonate a funinoxypropanediol compound, and then treat it with a base. By closing the ring, it was found that the desired 1,4-benzodioxane derivative could be synthesized industrially and advantageously, and the present invention was completed.
- R 2 , R 3 , and R 4 each represent a hydrogen atom, a halogen atom, a hydroxyl group, a nitro group, a cyano group, a formyl group, a carboxylic acid group, or an alkoxycarbonyl group having 1 to 4 carbon atoms.
- Xy group, alkyl group having 1 to 4 carbon atoms, alkoxy group having 1 to 4 carbon atoms, haloalkyl group having 1 to 4 carbon atoms, N, N-dialkylamino group having 1 to 4 carbon atoms, and alkyl moiety Represents an alkyl group having 1 to 4 carbon atoms, an alkoxycarbonyl group having 1 to 4 carbon atoms, an unsubstituted or substituted phenyl group having 1 to 4 carbon atoms, or R 2 , any two of R 3 and R 4 together represent a methylenedioxy group bonded to an adjacent carbon, or any two of R 2 , R 3 and R 4 represent represents the binding combined full We two Le group.
- R 5 Habe Nji Group (for example, 2-propenyl group) Ariru group, 0- two Torobe Njiru group, a t one-butyldimethyl Nriru group or base Nji Ruo carboxymethyl carbonylation Le group.
- R 2, R 3, be any one of a hydroxyl group of R 4, if the water group is bound to the carbon atom adjacent to the carbon atom bonded to R 5, 0 groups, an oxygen atom of R 5 is hydroxyl and R 5 0 group Mechirenjiokishi group together with the oxygen atoms, isopropylidene O alkoxy group, (It may form a cyclohexylideneoxy group or a diphenylmethylenedioxy group.)
- R represents an alkyl group having 14 carbon atoms or a unsubstituted or substituted with an alkyl group having 14 carbon atoms, and R 2 R 3 R 4 and R 5 are the same as described above.
- R 1 represents a hydrogen atom or RS0 2, R, R 2, R 3 and R 4 have the same meanings as defined above)
- the present invention also provides a method for producing a 1,4-benzodioxane derivative represented by the formula:
- a diol compound (2) is converted into a sulfonyl halide compound, for example, arylsulfonyl halides such as benzenesulfonyl chloride and toluenesulfonyl chloride, or a compound having 1 to 1 carbon atoms such as methanesulfonyl chloride in the presence of a base.
- arylsulfonyl halides such as benzenesulfonyl chloride and toluenesulfonyl chloride
- a compound having 1 to 1 carbon atoms such as methanesulfonyl chloride
- an organic base such as triethylamine or pyridine is used.
- the c reaction may be solvent-free or may be an ether-based solvent such as tetrahydrofuran, dioxane, t-butyl methyl ether, dimethyl ether, methylene chloride, chloroform, A chlorinated solvent such as dichloroethane, an aromatic hydrocarbon solvent such as benzene and toluene may be used.
- the reaction temperature is from 0 to 100 ° C, preferably from 10 to 50 ° C. This reaction proceeds without a catalyst, but the addition of NN-dimethylaminopyridine accelerates the reaction and improves the yield.
- the monosulfonate compound (3) and the disulfonate compound (4) are obtained as a mixture, both can be separated by liquid column chromatography or the like, but the mixture can be used in the next step as it is.
- R 5 is N, N-dimethylformamide ⁇ Mi de Ya as tetrahydrofuran organic solvent such or a mixture of these organic solvents and water, sodium fluoride It can be eliminated using a fluoride salt such as potassium fluoride, tetrabutylammonium fluoride and the like.
- a protecting group R 5 is a methylenedioquine group, an isopropylidenedioxy group, a cyclohexylidenedioquine group or a diphenylmethylenedioxy group
- the acid is usually used under the acidic conditions used for this kind of leaving group. Can be detached.
- Solvents used include non-protonic polar solvents such as N, N-dimethylformamide, dimethylsulfoxide, sulfolane, and hexamethylphosphoramide, tetrahydrofuran, dioxane, t-butylmethylether, and getylether.
- Ether solvents chlorinated solvents such as methylene chloride, chloroform and dichloroethane, alcohol solvents such as methanol, ethanol, isopropanol and t-butanol, and aqueous media.
- hydrides of alkali metals hydroxides of alkali metals, hydroxides of alkaline earth metals, carbonates of alkali metals, carbonates of alkaline earth metal or C1-C4 Alkyl metal salts of lower alkyl alcohols of 4 and tertiary amines having lower alkyl groups of 1 to 4 carbon atoms
- the amount of the base to be used is 1-5 mol, more preferably 1-3 mol, relative to compounds (5) and (6).
- the reaction temperature ranges from 20 to 80 ° C, preferably from 0 to 50 ° C.
- ring closure of compound (5) it is considered that epoxides are formed during the reaction, and the hydroxyl groups in the benzene ring attack the epoxides to close the ring.
- a 6-membered ring and a 7-membered ring may be formed, but a 6-membered ring is preferentially obtained.
- arylsulfonyl halide such as benzenesulfonyl chloride and toluenesulfonyl chloride or methanesulfonyl
- the diol compound (2) as a raw material of the present invention can be synthesized by the method shown in the following reaction step.
- Solvents used include ⁇ , ⁇ ⁇ '— dimethylformamide, dimethylsulfoxide, sulfolane, Non-protonic polar solvents such as hexamethylphosphoramide, ether solvents such as tetrahydrofuran, dioxane, t-butyl methyl ether, and ethyl ether; chlorinated solvents such as methylene chloride, chloroform, dichloroethane, etc. Examples include alcoholic solvents such as methanol, ethanol, isopropanol and t-butanol, and aqueous media.
- hydrides of alkali metals hydroxides of alkali metals, hydroxides of alkaline earth metals, carbonates of alkali metals, carbonates of alkaline earth metal or C1-C4
- a lower alkyl alcohol metal salt of 4 or a tertiary amine having a lower alkyl group having 1 to 4 carbon atoms can be used.
- Examples include sodium hydride, sodium hydroxide, potassium hydroxide, calcium hydroxide, sodium carbonate, potassium carbonate, sodium methoxide, sodium ethoxide, triethylamine, and ethyl isopropylamine.
- the amount of the base used is 1 to 4 mol, more preferably 1.1 to 2.5 mol, based on the catechol derivative (7) as a raw material.c
- the reaction temperature is 120 to 150, preferably 2 to 150. 0 to 100 ° C. If the reaction temperature is too low, the reaction rate is extremely slow, which is not practical.If the reaction temperature is too high, the yield is significantly reduced, possibly due to the polymerization of glindol generated during the reaction.c
- the diol compound (2) as a starting material in the present invention can also be synthesized by a known method, that is, by reacting a catechol derivative (7) with glycidol. However, while glycidol is unstable and easily polymerized, 3-chloro-1,2-propanediol (8) is stable and inexpensive, and the method using it is industrially advantageous as described above. is there.
- an optically active 1,4-benzodioxane derivative can be produced.
- Such an optically active diol compound (2) can be obtained, for example, by reacting an optically active 3-chloro-1,2-propanediol with a catechol derivative (7) under the same reaction conditions as described above.
- 3-chloro-1,2-propanediol having high optical purity is used as a raw material, a remarkable racemization reaction does not occur during the reaction, and a 1,4-benzodioxane derivative having high optical purity can be synthesized.
- 3-Chloro-1.2-propanediol having a high optical purity (98% ee or more) is disclosed, for example, in Japanese Patent Publication No. Hei 4-197398 and Japanese Patent Publication No. Hei 4-197399 by the present applicant. Can be obtained by the method described in (1). Further, according to the method of the present invention, an S-1,4-benzodioxane derivative is obtained from R-3-chloro-1,2,2-propanediol, and an S-3,4-benzodioxane derivative is obtained from S-3-chloro-1,1,2-propanediol. An R-1,4-benzodioxane derivative is obtained.
- the ethyl acetate layer was washed twice with water, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to obtain 15.2 g of a mixture of ditosyl-form and monomonotosyl-form (production ratio: 6: 1) as a pale yellow oil.
- a 1,4-benzodioxane derivative can be produced in a high yield by an industrially easy method without isolating an intermediate formed during the process. can do.
- a 1,4-benzodioxane derivative having a high optical purity can be obtained without remarkable racemization during the reaction.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Light Receiving Elements (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT96906901T ATE206417T1 (de) | 1995-03-24 | 1996-03-21 | Verfahren zur herstellung von 1,4- benzodioxanderivaten. |
DE69615695T DE69615695T2 (de) | 1995-03-24 | 1996-03-21 | Verfahren zur herstellung von 1,4-benzodioxanderivaten. |
US08/913,882 US5780650A (en) | 1995-03-24 | 1996-03-21 | Process for preparation of 1,4-benzodioxane derivative |
CA002215604A CA2215604C (en) | 1995-03-24 | 1996-03-21 | Process for preparation of 1,4-benzodioxane derivative |
AU50138/96A AU5013896A (en) | 1995-03-24 | 1996-03-21 | Process for producing 1,4-benzodioxane derivatives |
EP96906901A EP0841334B1 (en) | 1995-03-24 | 1996-03-21 | Process for producing 1,4-benzodioxane derivatives |
NO19974386A NO316990B1 (no) | 1995-03-24 | 1997-09-23 | Fremgangsmate for fremstilling av en blanding av 1,4-benzodioksanderivater og et 1,4-benzodioksanderivat |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP7/66270 | 1995-03-24 | ||
JP6627095 | 1995-03-24 | ||
JP03945896A JP3235448B2 (ja) | 1995-03-24 | 1996-02-27 | 1,4−ベンゾジオキサン誘導体の製法 |
JP8/39458 | 1996-02-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996030360A1 true WO1996030360A1 (fr) | 1996-10-03 |
Family
ID=26378853
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1996/000727 WO1996030360A1 (fr) | 1995-03-24 | 1996-03-21 | Technique de production de derives de 1,4-benzodioxane |
Country Status (12)
Country | Link |
---|---|
US (1) | US5780650A (ja) |
EP (1) | EP0841334B1 (ja) |
JP (1) | JP3235448B2 (ja) |
KR (1) | KR100383300B1 (ja) |
AT (1) | ATE206417T1 (ja) |
AU (1) | AU5013896A (ja) |
CA (1) | CA2215604C (ja) |
DE (1) | DE69615695T2 (ja) |
ES (1) | ES2165489T3 (ja) |
NO (1) | NO316990B1 (ja) |
TW (1) | TW472052B (ja) |
WO (1) | WO1996030360A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6020503A (en) * | 1997-05-12 | 2000-02-01 | Daiso Co., Ltd. | Process for producing 1,4-benzodioxane derivatives |
WO2008016199A1 (en) * | 2006-08-02 | 2008-02-07 | Ahn-Gook Pharmaceutical Co., Ltd. | Process for the preparation of chiral 2-hydroxymethyl-1,4-benzodioxane compound |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4572475B2 (ja) * | 2000-03-03 | 2010-11-04 | ダイソー株式会社 | 1,4−ベンゾジオキサン誘導体の製造法 |
US20060167282A1 (en) * | 2002-07-29 | 2006-07-27 | Tatsuyoshi Tanaka | Process for industrially producing optically active 1,4- benzodioxane derivative |
AR049646A1 (es) * | 2004-06-16 | 2006-08-23 | Janssen Pharmaceutica Nv | Derivados de sulfamato y sulfamida utiles para el tratamiento de la epilepsia y trastornos relacionados |
MY147767A (en) * | 2004-06-16 | 2013-01-31 | Janssen Pharmaceutica Nv | Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders |
JP4604583B2 (ja) * | 2004-07-20 | 2011-01-05 | ダイソー株式会社 | 1−アミド−3−(2−ヒドロキシフェノキシ)−2−プロパノール誘導体、ならびに2−アミドメチル−1,4−ベンゾジオキサン誘導体の製造法 |
ES2310366T3 (es) * | 2004-08-24 | 2009-01-01 | Janssen Pharmaceutica Nv | Nuevos derivados de heteroaril sulfonamida benzo-condensada utiles como agentes anticonvulsivos. |
GT200600159A (es) * | 2005-04-22 | 2007-03-14 | Derivados benzodioxano y benzodioxolano y usos de los mismos | |
AU2006249577A1 (en) * | 2005-05-20 | 2006-11-30 | Janssen Pharmaceutica N.V. | Process for preparation of sulfamide derivatives |
US7846131B2 (en) * | 2005-09-30 | 2010-12-07 | Covidien Ag | Administration feeding set and flow control apparatus with secure loading features |
US8716231B2 (en) * | 2005-12-19 | 2014-05-06 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain |
US8497298B2 (en) * | 2005-12-19 | 2013-07-30 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels |
US8691867B2 (en) * | 2005-12-19 | 2014-04-08 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction |
US8937096B2 (en) * | 2005-12-19 | 2015-01-20 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder |
US20070155827A1 (en) * | 2005-12-19 | 2007-07-05 | Smith-Swintosky Virginia L | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression |
AR058389A1 (es) * | 2005-12-19 | 2008-01-30 | Janssen Pharmaceutica Nv | Uso de derivados heterociclicos benzo-fusionados de sulfamida para el tratamiento de la obesidad |
US20070155823A1 (en) * | 2005-12-19 | 2007-07-05 | Smith-Swintosky Virginia L | Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents |
AU2007253814A1 (en) * | 2006-05-19 | 2007-11-29 | Janssen Pharmaceutica N.V. | Co-therapy for the treatment of epilepsy |
US20090247618A1 (en) * | 2008-03-26 | 2009-10-01 | Ballentine Scott A | Process for preparation of benzo-fused heteroaryl derivatives |
US20090247617A1 (en) * | 2008-03-26 | 2009-10-01 | Abdel-Magid Ahmed F | Process for the preparation of benzo-fused heteroaryl sulfamates |
US20090247616A1 (en) * | 2008-03-26 | 2009-10-01 | Smith-Swintosky Virginia L | Use of benzo-fused heterocyle sulfamide derivatives for the treatment of anxiety |
NZ590682A (en) * | 2008-06-23 | 2012-09-28 | Janssen Pharmaceutica Nv | Crystalline form of (2S)-(-)-N-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide |
US8815939B2 (en) * | 2008-07-22 | 2014-08-26 | Janssen Pharmaceutica Nv | Substituted sulfamide derivatives |
US8180891B1 (en) | 2008-11-26 | 2012-05-15 | Free Stream Media Corp. | Discovery, access control, and communication with networked services from within a security sandbox |
WO2010068881A1 (en) * | 2008-12-12 | 2010-06-17 | Forest Laboratories Holdings Limited | Novel benzodioxane and benzoxazine derivatives useful as cc chemokine receptor ligands |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH069613A (ja) * | 1991-10-22 | 1994-01-18 | Chugai Pharmaceut Co Ltd | ベンゾジオキサン誘導体 |
-
1996
- 1996-02-27 JP JP03945896A patent/JP3235448B2/ja not_active Expired - Fee Related
- 1996-03-21 US US08/913,882 patent/US5780650A/en not_active Expired - Fee Related
- 1996-03-21 WO PCT/JP1996/000727 patent/WO1996030360A1/ja active IP Right Grant
- 1996-03-21 ES ES96906901T patent/ES2165489T3/es not_active Expired - Lifetime
- 1996-03-21 AU AU50138/96A patent/AU5013896A/en not_active Abandoned
- 1996-03-21 AT AT96906901T patent/ATE206417T1/de not_active IP Right Cessation
- 1996-03-21 EP EP96906901A patent/EP0841334B1/en not_active Expired - Lifetime
- 1996-03-21 KR KR1019970706553A patent/KR100383300B1/ko not_active IP Right Cessation
- 1996-03-21 DE DE69615695T patent/DE69615695T2/de not_active Expired - Fee Related
- 1996-03-21 CA CA002215604A patent/CA2215604C/en not_active Expired - Fee Related
- 1996-03-22 TW TW085103457A patent/TW472052B/zh not_active IP Right Cessation
-
1997
- 1997-09-23 NO NO19974386A patent/NO316990B1/no unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH069613A (ja) * | 1991-10-22 | 1994-01-18 | Chugai Pharmaceut Co Ltd | ベンゾジオキサン誘導体 |
Non-Patent Citations (1)
Title |
---|
TETRAHEDRON LETTERS, Vol. 29, No. 30, (1988), ANTONIO D. et al., pages 3671-3674. * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6020503A (en) * | 1997-05-12 | 2000-02-01 | Daiso Co., Ltd. | Process for producing 1,4-benzodioxane derivatives |
WO2008016199A1 (en) * | 2006-08-02 | 2008-02-07 | Ahn-Gook Pharmaceutical Co., Ltd. | Process for the preparation of chiral 2-hydroxymethyl-1,4-benzodioxane compound |
Also Published As
Publication number | Publication date |
---|---|
DE69615695D1 (de) | 2001-11-08 |
EP0841334B1 (en) | 2001-10-04 |
TW472052B (en) | 2002-01-11 |
NO974386D0 (no) | 1997-09-23 |
JP3235448B2 (ja) | 2001-12-04 |
ATE206417T1 (de) | 2001-10-15 |
US5780650A (en) | 1998-07-14 |
NO974386L (no) | 1997-11-21 |
KR19980703150A (ko) | 1998-10-15 |
EP0841334A1 (en) | 1998-05-13 |
EP0841334A4 (en) | 1998-07-08 |
DE69615695T2 (de) | 2002-07-11 |
ES2165489T3 (es) | 2002-03-16 |
AU5013896A (en) | 1996-10-16 |
CA2215604A1 (en) | 1996-10-03 |
KR100383300B1 (ko) | 2004-02-11 |
CA2215604C (en) | 2006-05-23 |
NO316990B1 (no) | 2004-07-19 |
JPH08325260A (ja) | 1996-12-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1996030360A1 (fr) | Technique de production de derives de 1,4-benzodioxane | |
EP1840125B1 (fr) | Intermédiaires pour la production de dioxane-2-alkylcarbamates | |
JP3611332B2 (ja) | アミド誘導体の製造方法及び中間体化合物 | |
CA2306741A1 (en) | Process for the preparation of (2r, 3s)-3-amino-1,2-oxirane | |
EP0111326A1 (en) | Process for the manufacture of chiral azetidinones | |
KR100429320B1 (ko) | 헤테로-이환알콜거울상이성질체의입체선택적제조방법 | |
WO1997026254A1 (fr) | Procede de production de sulfonate de glycidyle | |
US6700001B2 (en) | Process for stereoselective synthesis of 2-hydroxymethyl chromans | |
WO1998012171A1 (fr) | Procede de preparation d'ethers 3-amino-2-hydroxy-1-propyliques | |
US5136061A (en) | Optically active pentane derivatives and intermediates thereof, and process for manufacturing same | |
KR102529680B1 (ko) | 네비볼롤 합성방법 및 그의 중간 화합물 | |
WO1998012186A1 (fr) | Procede de preparation d'ethers glycidyliques | |
JP3084578B2 (ja) | 光学活性化合物の製造法 | |
US5243096A (en) | Optically active pentane derivatives and intermediates thereof, and process for manufacturing same | |
KR100283991B1 (ko) | 비스-트리아졸 유도체의 제조방법 | |
US4777293A (en) | Method for the synthesis of pharmacologically active compounds and intermediates for such synthesis | |
WO2002072505A1 (fr) | Systeme de resolution optique et procede de resolution optique d'alcool utilisant celui-ci | |
WO1990007506A1 (en) | Production of glycidyl ether | |
JP2640688B2 (ja) | カルバメート誘導体類及びそれらの製造方法 | |
JP3904491B2 (ja) | アミド誘導体の製造方法及び中間体化合物 | |
JP3710708B2 (ja) | 光学活性fr−900482およびその類縁体化合物並びに合成中間体化合物とその製造方法 | |
JP2001081086A (ja) | 1,4−ベンゾジオキサン類の製法 | |
JP4148202B2 (ja) | ブタントリオール誘導体の製造法 | |
KR100780538B1 (ko) | 키랄 2-히드록시메틸-1,4-벤조디옥산 화합물의 제조방법 | |
JP2004500413A (ja) | N−ヒドロキシルアミンの選択的n−ホルミル化の方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AT AU BB BG BR CA CH CZ DE DK ES GB HU KR LK LU MG MN MW NO PL RO RU SD SE SK US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2215604 Country of ref document: CA Ref country code: CA Ref document number: 2215604 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1019970706553 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 08913882 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1996906901 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1996906901 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1019970706553 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 1996906901 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1019970706553 Country of ref document: KR |